Yumanity Therapeutics develops next-generation immunotherapies that target cancer immune resistance through VISTA blocking mechanisms. The company focuses on addressing diseases caused by protein misfolding, enhancing the efficacy of cancer treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer cells often develop resistance to the body's immune system, limiting the effectiveness of immunotherapies. Current cancer treatments may not adequately address the mechanisms that allow tumors to evade immune detection and destruction.
Solution
Yumanity Therapeutics is developing a new class of immunotherapies designed to overcome cancer immune resistance by targeting the VISTA (V-domain Ig suppressor of T cell activation) pathway. Their approach focuses on blocking VISTA, a key checkpoint protein that inhibits T cell activation and allows cancer cells to evade immune responses. By blocking VISTA, Yumanity's therapies aim to enhance the ability of the immune system to recognize and eliminate cancer cells, potentially improving patient outcomes. The company's research targets diseases where protein misfolding contributes to immune resistance, offering a novel strategy to enhance the efficacy of existing cancer treatments.
Target Audience
The primary target audience includes patients with cancers that exhibit immune resistance and healthcare providers specializing in oncology and immunotherapy.
Features
- VISTA-blocking antibodies designed to reactivate T cells in the tumor microenvironment
- Targeted therapies that address mechanisms of cancer immune resistance
- Focus on diseases caused by protein misfolding to enhance immunotherapy efficacy